Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Assets (2018 - 2025)

China SXT Pharmaceuticals has reported Assets over the past 8 years, most recently at $26.4 million for Q3 2025.

  • For Q3 2025, Assets fell 14.98% year-over-year to $26.4 million; the TTM value through Sep 2025 reached $26.4 million, down 14.98%, while the annual FY2025 figure was $21.7 million, 6.33% down from the prior year.
  • Assets for Q3 2025 was $26.4 million at China SXT Pharmaceuticals, up from $21.7 million in the prior quarter.
  • Over five years, Assets peaked at $34.5 million in Q1 2021 and troughed at $14.6 million in Q3 2023.
  • A 5-year average of $25.9 million and a median of $24.7 million in 2024 define the central range for Assets.
  • Biggest five-year swings in Assets: tumbled 34.23% in 2023 and later surged 112.49% in 2024.
  • Year by year, Assets stood at $22.7 million in 2021, then fell by 2.16% to $22.2 million in 2022, then tumbled by 34.23% to $14.6 million in 2023, then surged by 112.49% to $31.0 million in 2024, then fell by 14.98% to $26.4 million in 2025.
  • Business Quant data shows Assets for SXTC at $26.4 million in Q3 2025, $21.7 million in Q1 2025, and $31.0 million in Q3 2024.